



## **Xintela strengthens business development and reorganizes**

**Xintela announces today that Thomas Areschoug has been recruited to the business development team as Business Development Manager. In addition, the company is reorganizing in order to develop its projects more efficiently.**

*- We are very pleased to have Thomas Areschoug join the team. His broad international network and experience is exactly what Xintela now needs to market our technology and identify good industrial partners for our projects, says Xintela's CEO Evy Lundgren-Åkerlund.*

### **Broad life sciences network**

Thomas Areschoug has recently worked with business development at Invest in Skåne, where he built up a broad network of pharmaceutical companies and investors. He marketed companies in Southern Sweden and facilitated contacts and partnerships with international players. Thomas Areschoug also has a broad background in biomedical research with a focus on microbiology and immunology. In addition, he has been active in biotechnology companies and worked with business development, project management and financing. He also has experience of Board work.

*- I'm really looking forward to taking on this task to promote Xintela's projects and identify possible partners and licensees. The company has an exciting technology with great potential. Many international companies are already aware of Xintela's projects in regenerative medicine and cancer, says Thomas Areschoug.*

Xintela also announces that the company is reorganizing to more effectively move its projects forward. Carl-Magnus Högerkorp leaves the role of Chief Scientific Officer and will assume the role of Production Manager with a focus on GMP production of stem cells for the clinical studies in horses and humans. Evy Lundgren-Åkerlund takes over the research responsibility. Chairman Greg Batcheller is increasing his operational engagement in the company as Executive Chairman.

### **Xintela AB (publ)**

Evy Lundgren-Åkerlund, CEO  
Tel: +46 70-329 18 71  
E-mail: [evy@xintela.se](mailto:evy@xintela.se)  
Medicon Village  
223 81 Lund, Sweden  
[www.xintela.se](http://www.xintela.se)

### **Media and Investor Relations related queries should be directed to:**

Mårten Svanberg, Laika Consulting  
Tel: +46 70-362 70 05  
E-mail: [marten.svanberg@laika.se](mailto:marten.svanberg@laika.se)  
[www.laika.se](http://www.laika.se)

### **About Xintela**

Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces. The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

Press Release

Xintela AB (publ)

556780-3480

2017-03-21 08:30



*This information is information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the contact persons set out above on 21 Mars 2017, at 08:30 a.m CET.*